Published in J Lipid Res on September 25, 2009
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (2014) 6.84
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol (2012) 2.78
A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology (2013) 2.39
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes (2010) 2.10
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev (2014) 1.58
Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat Commun (2015) 1.57
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest (2014) 1.55
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res (2012) 1.55
Bile acid metabolism and signaling. Compr Physiol (2013) 1.42
FXR signaling in the enterohepatic system. Mol Cell Endocrinol (2012) 1.32
Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep (2011) 1.30
Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology (2014) 1.26
Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes (2012) 1.18
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis (2013) 1.10
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev (2013) 1.10
Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids (2011) 1.09
Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol (2010) 1.08
Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res (2013) 1.07
Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med (2015) 1.06
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun (2015) 1.00
Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol (2013) 0.99
Exploring gut microbes in human health and disease: Pushing the envelope. Genes Dis (2014) 0.99
Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol (2014) 0.94
Inhibition of gastric lipase as a mechanism for body weight and plasma lipids reduction in Zucker rats fed a rosemary extract rich in carnosic acid. PLoS One (2012) 0.94
Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin (2014) 0.92
FXR and liver carcinogenesis. Acta Pharmacol Sin (2014) 0.91
Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood) (2014) 0.90
Nuclear receptors reverse McGarry's vicious cycle to insulin resistance. Cell Metab (2012) 0.87
Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes. Int J Endocrinol (2014) 0.84
An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. Gastroenterology (2016) 0.83
HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes. BMC Infect Dis (2012) 0.83
Gut Microbiota Modification: Another Piece in the Puzzle of the Benefits of Physical Exercise in Health? Front Physiol (2016) 0.82
An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training. Eur J Nutr (2012) 0.82
Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta (2016) 0.81
Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B (2015) 0.81
Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. Sci Rep (2016) 0.80
Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial. Eur J Endocrinol (2013) 0.80
Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos (2012) 0.79
Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice. J Biol Chem (2015) 0.79
Unsuppressed lipolysis in adipocytes is linked with enhanced gluconeogenesis and altered bile acid physiology in Insr(P1195L/+) mice fed high-fat-diet. Sci Rep (2015) 0.79
Molecular Pathogenesis of NASH. Int J Mol Sci (2016) 0.78
Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep (2015) 0.78
Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands. Sci Rep (2016) 0.78
Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism. Mol Metab (2015) 0.77
Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.77
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. PLoS One (2010) 0.77
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.77
Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol (2015) 0.77
A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. BMC Genomics (2016) 0.76
Analysis of the serum bile Acid composition for differential diagnosis in patients with liver disease. Gastroenterol Res Pract (2015) 0.76
Farnesoid X receptor-Acting through bile acids to treat metabolic disorders. Drugs Future (2010) 0.76
Bile acids and bariatric surgery. Mol Aspects Med (2017) 0.75
Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms (2015) 0.75
Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) (2016) 0.75
Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease. Sci Rep (2015) 0.75
NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease. Biochem Biophys Res Commun (2014) 0.75
An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice. Diabetes (2016) 0.75
Obesity diabetes and the role of bile acids in metabolism. J Transl Int Med (2016) 0.75
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases. Front Pharmacol (2017) 0.75
Farnesoid X Receptor an Emerging Target to Combat Obesity. Dig Dis (2017) 0.75
Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. Front Pharmacol (2016) 0.75
Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol (2016) 0.75
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci Rep (2017) 0.75
Non-alcoholic fatty liver and the gut microbiota. Mol Metab (2016) 0.75
Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters. J Lipid Res (2016) 0.75
Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats. PLoS One (2017) 0.75
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma. Sci Rep (2015) 0.75
Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa rats. Int J Biomed Sci (2014) 0.75
Altenusin, a non-steroidal microbial metabolite, attenuates non-alcoholic fatty liver disease by activating the farnesoid X receptor. Mol Pharmacol (2017) 0.75
Chemoproteomic Profiling of Bile Acid Interacting Proteins. ACS Cent Sci (2017) 0.75
FXR Agonists: From Bench to Bedside, a Guide for Clinicians. Dig Dis Sci (2016) 0.75
The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Children (Basel) (2017) 0.75
Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature (2006) 15.48
Cellular mechanisms of insulin resistance. J Clin Invest (2000) 12.61
Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem (2002) 9.76
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol (2008) 8.43
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Bile acids: regulation of synthesis. J Lipid Res (2009) 4.31
Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A (1994) 4.08
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77
Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest (2006) 3.44
Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med (2004) 3.17
Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med (2005) 3.12
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology (2008) 2.83
Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab (2006) 2.70
The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med (1999) 2.70
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol (2008) 2.33
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30
Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology (2007) 2.14
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem (1995) 1.82
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol (2001) 1.75
Treatment of non-alcoholic fatty liver disease. Postgrad Med J (2006) 1.63
Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol (2008) 1.49
Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology (2009) 1.48
Metformin therapy and clinical uses. Diab Vasc Dis Res (2008) 1.44
Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med (2007) 1.23
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol (2006) 1.20
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab (2008) 1.11
Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol (2005) 1.02
Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem (2008) 1.01
Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem Biophys Res Commun (2005) 0.97
Farnesoid X receptor agonists in biliary tract disease. Curr Opin Gastroenterol (2009) 0.96
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr Med Chem (2010) 0.93
Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharm (2007) 0.90
Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem (2008) 0.85
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
Concern NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 2.09
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol (2009) 1.69
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology (2006) 1.59
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol (2004) 1.52
Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 1.47
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.47
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci (2009) 1.45
Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci (2003) 1.43
Galectin-1 suppresses experimental colitis in mice. Gastroenterology (2003) 1.41
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov (2002) 1.33
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther (2005) 1.30
Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J (2009) 1.29
Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol (2008) 1.26
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res (2009) 1.23
Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem (2006) 1.21
Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J (2004) 1.21
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol (2006) 1.20
Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. J Med Chem (2010) 1.18
PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol (2006) 1.17
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One (2013) 1.13
The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta (2010) 1.11
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One (2011) 1.11
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation (2013) 1.11
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther (2005) 1.11
Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord (2005) 1.11
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. J Med Chem (2011) 1.09
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One (2011) 1.08
Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol (2014) 1.08
Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol (2010) 1.07
Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J Med Chem (2011) 1.04
Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler Thromb Vasc Biol (2004) 1.03
VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One (2012) 1.02
Farnesoid X receptor: from structure to potential clinical applications. J Med Chem (2005) 1.02
Primary brain abscess with Nocardia farcinica in an immunocompetent patient. Clin Neurol Neurosurg (2002) 1.01
Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol (2011) 1.01
Retracted A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol (2002) 1.01
The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol (2005) 1.00
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther (2006) 1.00
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One (2013) 0.99
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol (2009) 0.98
Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion (2002) 0.98
A magic bullet for mucosal protection...and aspirin is the trigger! Trends Pharmacol Sci (2003) 0.97
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. Diabetes (2013) 0.97
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. Hepatology (2008) 0.96
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One (2012) 0.95
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem (2004) 0.95
Towards new ligands of nuclear receptors. Discovery of malaitasterol A, an unique bis-secosterol from marine sponge Theonella swinhoei. Org Biomol Chem (2011) 0.95
Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol (2003) 0.94
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can J Gastroenterol (2004) 0.94
Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. J Pharmacol Exp Ther (2004) 0.93
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr Med Chem (2010) 0.93
Three polymorphic forms of the co-crystal 4,4'-bipyridine/pimelic acid and their structural, thermal, and spectroscopic characterization. Chemistry (2008) 0.93
Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine (2012) 0.93
Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation. FASEB J (2005) 0.92
Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei. J Med Chem (2011) 0.91
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation (2004) 0.91
Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta (2011) 0.91
Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. Arterioscler Thromb Vasc Biol (2005) 0.90
Retracted Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol (2004) 0.90
The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes. PLoS One (2012) 0.90
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS One (2013) 0.90
Role of PAR2 in pain and inflammation. Trends Pharmacol Sci (2002) 0.90
Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis (2005) 0.89
FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med (2010) 0.89
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J (2012) 0.88